Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems a...(atment of high surgical-risk patients wi...),Health

carotid artery disease. The Company plans to issue a press release at

this time.

-- Analyst Meeting. At 5:30 p.m., the Company will host an analyst

meeting in the Grand Ballroom of the Renaissance Hotel. The meeting is

open to the media and will include a DES clinical program update by Dr.

Donald Baim and a DES business update by Paul LaViolette. This meeting

is being webcast and can be accessed in the Investor Relations section

of Boston Scientific's website, http://www.bostonscientific.com. Please visit

the website for details on how to register for the webcast or to access

a replay, which will be archived for 90 days.

-- Symposium on Drug-Eluting Stents. From 8:00 - 10:00 p.m., the Company

will host a symposium entitled "Preclinical to Patients: The DES

Pathway" chaired by Keith D. Dawkins, M.D., in the Grand Ballroom of

the Renaissance Hotel. The symposium will include presentations on

drug development and actions of current DES molecules by Aloke V. Finn,

M.D.; the state of the DES market by Dr. Dawkins; late-breaking data on

next-generation DES by Dr. Turco; and impact of dual anti-platelet

therapy on DES outcomes by Steven R. Steinhubl, M.D. A reception will

be held prior to the symposium at 7:00 p.m.

The Company will also release additional safety and efficacy data from its comprehensive DES clinical trial program, which will be presented at TCT as e- posters. Details can be found on the official TCT program.

Boston Scientific will present its latest innovations and live case broadcasts at booth 3021 in the Exhibition Hall. Key product demonstrations will include drug-eluting stents, carotid artery stenting and peripheral interventions. In addition, Boston Scientific will i
'/>"/>